Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed July 4, 2023.
   Google Scholar
• Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev. 2019;28:190095. doi:10.1183/16000617.0095-2019
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2021;56:74–84. doi:10.1016/j.coph.2020.11.003
   PubMed Web of Science ®Google Scholar
• Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157:892–906. doi:10.1111/j.1476-5381.2009.00170.x
   PubMed Web of Science ®Google Scholar
• de Boer J, Philpott AJ, Van amsterdam RG, Shahid M, Zaagsma J, Nicholson CD. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol. 1992;106:1028–1034. doi:10.1111/j.1476-5381.1992.tb14451.x
   PubMed Web of Science ®Google Scholar
• Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. In: Francis S, Conti M, Houslay M, editors. Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology. Berlin: Springer; 2011:391–414.
   Google Scholar
• Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–694. doi:10.1016/S0140-6736(09)61255-1
   PubMed Web of Science ®Google Scholar
• Singh D, Nandeuil MA, Pigeon-Francisco C, et al. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the pioneer dose finding study. Am J Respir Crit Care Med. 2019;199:A4529.
   Web of Science ®Google Scholar
• DALIRESP® (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020. Accessed from: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/704932ce-e104-4c6f-840a-575170971344/704932ce-e104-4c6f-840a-575170971344_viewable_rendition__v.pdf. Accessed July 4, 2023.
   Google Scholar
• Thomas B, Koh MS, O’Callaghan C, et al. Dysfunctional bronchial cilia are a feature of Chronic Obstructive Pulmonary Disease (COPD). COPD. 2021;18(6):657–663. doi:10.1080/15412555.2021.1963695
   PubMedGoogle Scholar
• Dransfield M, Rowe S, Vogelmeier CF, et al. Cystic fibrosis transmembrane conductance regulator: roles in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2022;205(6):631–640. doi:10.1164/rccm.202109-2064TR
   PubMed Web of Science ®Google Scholar
• Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol. 2014;114(5):365–376. doi:10.1111/bcpt.12209
   PubMed Web of Science ®Google Scholar
• Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev V, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther. 2019;197:225–242. doi:10.1016/j.pharmthera.2019.02.002
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. doi:10.1124/pr.119.018150
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase ¾ inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-A]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-A]isoquinolin-4-one]. J Pharmacol Exp Ther. 2006;318(2):840–848. doi:10.1124/jpet.105.099192
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi:10.1016/S2213-2600(13)70187-5
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-2018
   PubMed Web of Science ®Google Scholar
• Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020;21(1):47. doi:10.1186/s12931-020-1307-4
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Kerwin EM, Rheault T, Bengtsson T, Rickard K. A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy. Int J Chron Obstruct Pulmon Dis. 2021;16:1137–1148. doi:10.2147/COPD.S307160
   PubMed Web of Science ®Google Scholar
• Turner MJ, Matthes E, Billet A, et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2016;310(1):L59–70. doi:10.1152/ajplung.00324.2015
   PubMed Web of Science ®Google Scholar
• Anzueto A, Barjaktarevic IZ, Siler TM, et al.; for the ENHANCE Investigators. Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: randomized, double-blind, placebo-controlled, multicenter, phase III trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023. doi:10.1164/rccm.202306-0944OC
   Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase ¾ inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414–423. doi:10.1124/jpet.113.204644
   PubMed Web of Science ®Google Scholar
• Keir S, Page C. RPL554, a dual phosphodiesterase (PDE) ¾ inhibitor acts synergistically with muscarinic receptor antagonists and beta-adrenoceptor agonists to produce bronchodilation in vivo. Am J Respir Crit Care Med. 2014;189:A4218.
   Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) ¾ inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23. doi:10.1016/j.pupt.2015.03.007
   PubMed Web of Science ®Google Scholar
• Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on Guinea pig tracheal smooth muscle contractility. Br J Pharmacol. 2016;173(15):2335–2351. doi:10.1111/bph.13512
   PubMed Web of Science ®Google Scholar
• Rheault T, MacDonald-Berko M. Anti-inflammatory pharmacology of ensifentrine. CHEST J. 2020;158(4):A2284. doi:10.1016/j.chest.2020.08.1936
   Web of Science ®Google Scholar
• Turner MJ, Luo Y, Thomas DY, Hanrahan JW. The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants. Am J Physiol Lung Cell Mol Physiol. 2020;318(5):L908–L920. doi:10.1152/ajplung.00285.2019
   PubMed Web of Science ®Google Scholar
• Turner MJ, Dauletbaev N, Lands LC, Hanrahan JW. The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4. J Pharmacol Exp Ther. 2020;375(3):414–429. doi:10.1124/jpet.120.000080
   PubMed Web of Science ®Google Scholar
• Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol Ther. 2021;224:107826. doi:10.1016/j.pharmthera.2021.107826
   PubMed Web of Science ®Google Scholar
• Rickard K, Darpo B, Xue H, Bengtsson T, Rheault T. The dual phosphodiesterase (PDE) 3 and 4 inhibitor ensifentrine does not prolong QT interval in healthy volunteers. Am J Respir Crit Care Med. 2022;205:A5605.
   Google Scholar
• Watz H, Rickard K, Rheault T, Bengtsson T, Singh D. Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD – a detailed analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2199–2206. doi:10.2147/COPD.S263025
   PubMed Web of Science ®Google Scholar
• Rickard K, Bengtsson T, Rheault T. Cardiovascular safety profile of ensifentrine in patients with COPD: results from two four-week, dose-ranging, randomized, placebo-controlled trials. Am J Respir Crit Care Med. 2021;2021:A2256.
   Google Scholar
• Leidy NK, Murray LT, Monz BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15:124. doi:10.1186/s12931-014-0124-z
   PubMed Web of Science ®Google Scholar
• Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103. doi:10.1081/COPD-200050666
   PubMedGoogle Scholar
• Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. CHEST J. 2007;132(2):456–463. doi:10.1378/chest.06-0702
   PubMed Web of Science ®Google Scholar
• Terry PD, Dhand R. Inhalation therapy for stable COPD: 20 years of GOLD reports. Adv Ther. 2020;37(5):1812–1828. doi:10.1007/s12325-020-01289-y
   PubMed Web of Science ®Google Scholar
• Barjaktarevic IZ, Milstone AP. Nebulized therapies in COPD: past, present, and the future. Int J Chron Obstruct Pulmon Dis. 2020;15:1665. doi:10.2147/COPD.S252435
   PubMed Web of Science ®Google Scholar
• Terry PD, Dhand R. Maintenance therapy with nebulizers in patients with stable COPD: need for reevaluation. Pulm Ther. 2020;6(2):177–192. doi:10.1007/s41030-020-00120-x
   PubMedGoogle Scholar
• Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468–1475. doi:10.1056/NEJM199111213252103
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365(9454):167–175. doi:10.1016/S0140-6736(05)17708-3
   PubMed Web of Science ®Google Scholar
• Martin C, Burgel PR, Roche N. Inhaled dual phosphodiesterase 3/4 inhibitors for the treatment of patients with COPD: a short review. Int J Chron Obstruct Pulmon Dis. 2021;16:2363–2373. doi:10.2147/COPD.S226688
   PubMed Web of Science ®Google Scholar